Hypertension drug developer Retension (RTSN.US) IPO priced at $11-13 per share, aiming to raise $40 million.

09:04 AM EDT, 10/06/2026 (MT Newswires) -- (Updates with pricing details in the headline and the first paragraph; and the offering close date in the last paragraph.) TORM (TRMD) said Tuesday that OCM Njord, a company indirectly owned by funds managed by Oaktree Capital Management and its affiliates, priced a secondary offering of 6.3 million class A shares for gross proceeds of about $253.5 million. The company said OCM Njord owns about 6% of its class A shares before the offering. TORM is not selling any shares and will not receive proceeds from the offering, the company said. The offering is expected to close on Wednesday, TORM said.

Reuters, October 6 - Lamb Weston (LW.N) raised its annual sales and profit forecasts on Tuesday, basing this decision on robust expected demand from its key clients—fast food restaurants—for its frozen potato products. As inflationary pressures intensify and household budgets become increasingly constrained, consumer demand continues to rise for lower-priced menu items such as fries at restaurants. Details are as follows: Lamb Weston expects fiscal 2027 revenue to achieve low single-digit growth, compared to its previous forecast of flat to 1% growth. According to data compiled by LSEG, analysts had previously expected revenue to decline by 1.5%. The company raised its adjusted annual earnings per share forecast to $3.05–$3.35, up from its prior range of $2.95–$3.25. Its adjusted earnings per share for the first quarter were $0.75, exceeding the analysts’ average estimate of $0.59 per share. Quarterly revenue rose 1% year-on-year to $1.67 billion, surpassing the expected $1.65 billion. Lamb Weston’s clients include fast-food operators such as McDonald’s (MCD.N). The company stated it is facing unexpected inflationary pressures in raw material and transportation costs, and plans to address these challenges through cooperation with suppliers and hedging activities. Shares of the fries manufacturer have risen about 6% this year and were up roughly 4% in pre-market trading following the earnings release. (For the convenience of non-native English speakers, Reuters has provided an automated translation of this report into several other languages. As automated translations may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated text and provides it only for readers’ convenience. Reuters assumes no responsibility for any harm or loss arising from the use of automated translation.)

On October 6 - Vaccine developer Vaxcyte (PCVX.O) shares fell 1.7% pre-market to $72.60, as the company seeks financing. PCVX launched a public offering on Monday night, including $500 millions in stock and pre-funded warrants, as well as $500 millions in convertible bonds (CBs) due October 15, 2032. On Monday, the PCVX share price soared approximately 31% and closed at $73.82 after the company announced its pneumonia vaccine VAX-31 met all primary endpoints in a late-stage clinical trial, generating immune responses at least comparable to Pfizer’s Prevnar 20 and Merck’s Capvaxive. The company plans to use the net proceeds from both offerings to fund the clinical development of VAX-31’s adult and pediatric programs—including the ongoing phase III adult study for VAX-31—clinical trials for its seasonal flu vaccine (OPUS-2), and other purposes. Jefferies, Leerink, BofA, Evercore, Goldman Sachs, and Guggenheim are joint book-running managers for this equity offering; Jefferies, Leerink, BofA, Goldman Sachs, and Evercore are joint lead underwriters for the convertible bonds. Based in San Carlos, California, PCVX has about 148.8 million shares outstanding and a market capitalization of $11 billions. As of Monday, the stock was up 60% year-to-date. According to London Stock Exchange Group (LSEG) data, out of 10 analysts, 9 rate the stock as “strong buy” or “buy” and 1 as “hold”; the median price target is $122. (For the convenience of non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or not capture the intended context, Reuters does not guarantee the accuracy of the automated text, which is provided for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)

09:00 AM EDT, 10/06/2026 (MT Newswires) -- Consumer stocks were edging higher premarket Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) up 0.1% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advancing by 0.6%. Nomad Foods (NOMD) stock was up more than 4% after the company said it now expects fiscal 2026 organic revenue to decline 2% to 3%, compared with its previous guidance for a decline of 2% to 5%.